Comparison of chimeric mouse-human and humanized anti-CD25 monoclonal antibodies for steroid-refractory acute graft-versus-host disease - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/41550930/
In conclusion, no significant differences were observed in efficacy or adverse events between chimeric mouse-human and humanized anti-CD25 monoclonal antibodies for the treatment of SR-aGVHD. Further studies with larger cohorts...
This retrospective study found similar day-28 response rates, safety, one-year survival, and non-relapse mortality between humanized xenopax and chimeric basiliximab for steroid-refractory acute graft-versus-host disease after allogeneic transplantation.
Case Report: Transfusion-associated graft-versus-host disease in severe combined immunodeficiency - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/41601678/
Transfusion-associated graft-versus-host disease (TA-GVHD) is a rare but fatal blood transfusion complication, with a mortality rate of 90-100%. Severe combined immunodeficiency (SCID) is a life-threatening primary immunodeficiency with profound cellular...
Case report of infant with SCID due to novel IL2RG mutation who developed fatal transfusion-associated graft-versus-host disease after non-irradiated transfusion, highlighting prevention importance and potential early markers like lymphocyte and eosinophil counts.
Axatilimab for Chronic Graft-Versus-Host Disease After Failure of at Least Two Prior Systemic Therapies: Results of a Phase I/II Study - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36459673/
Targeting profibrotic macrophages with axatilimab is a therapeutically promising novel strategy with a favorable safety profile for refractory cGVHD.
In phase I/II study, axatilimab, a CSF-1R inhibitor, showed manageable safety and high response rates (82% within six cycles) in heavily pretreated chronic GVHD, supporting macrophage-targeted therapy as promising strategy.
Acute Graft Versus Host Disease 1976-2020: Reduced Incidence and Predictive Factors
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10847269/
We studied the incidence of acute graft versus host disease (GvHD) and its outcome in three consecutive time frames (year 2010), in 3,120 patients allografted in two transplant Centers between...
Treatment was improved as suggested by reduced TRM and improved survival in a multivariate analysis, taking into consideration the current older patient population grafted from alternative donors.
Dual T Cell Depletion for Graft Versus Host Disease Prevention in Peripheral Blood Haploidentical Hematopoietic Cell Transplantation for Adults With Hematological Malignancies
Source : https://www.nature.com/articles/s41409-024-02216-3
The ideal immunosuppressive agents to complement post-transplant cyclophosphamide (PTCy) in PBSC-based haploidentical hematopoietic cell transplantation (haplo-HCT) remain debated. This study looks at our experience with ATG-PTCy-Cyclosporine (CsA) prophylaxis in PB...
These results confirmed that using post-transplant cyclophosphamide and ATG, alongside cyclosporine is safe and effective in preventing GVHD when using peripheral blood as the stem cell source in haploidentical hematopoietic cell transplantation.